Kristine Swiderek, PhD
Senior VP of Research
Dr. Kristine Swiderek has over 20 years of research and leadership experience in the biopharmaceutical industry and a proven track record of discovering and developing a wide variety of protein therapeutics.
Prior to joining AIS, Dr. Swiderek was Chief Scientific Officer at OncoResponse, where she developed and executed research and development strategies. Before that, Dr. Swiderek was Chief Scientific Officer at Theraclone leading the development of the I-STAR™ antibody discovery platform. She formed multiple R&D partnerships, helped advance therapeutic candidates into the clinic, and was instrumental in the spin-out of OncoResponse. Earlier in her career, Dr. Swiderek held several positions of increasing responsibility at ZymoGenetics, a Seattle-based public biotechnology company specializing in development of protein therapeutics. At ZymoGenetics she served as Vice President Protein Science, where she successfully built a world-class protein science department helping advance over a dozen therapeutic molecule candidates to be partnered, out-licensed, and into clinical development.
Earlier in her career, while holding a position at the City of Hope National Cancer Center, Dr. Swiderek established a state-of-the-art analytical core facility where she collaborated with a group of prestigious scientists. She has authored and co-authored over 60 peer reviewed articles and book chapters and has been a guest speaker at international scientific meetings and conventions.
Dr. Swiderek received her PhD in Protein Biochemistry from the Ruhr-Universität in Bochum, Germany. She completed her post-doctoral studies at City of Hope, Beckman Research Institute, in Duarte, California and the Department of Biochemistry and Molecular Biology at Indiana University, Indianapolis, Indiana.